1998-1999 Pilot Study Grants - Grants 1-22

Share

Funding from The Parkinson Alliance helped to finance the following Parkinsons' research. Grantees were selected by scientific review committees of participating organizations. Reports are available by clicking the underlined grants.

1. Role of Metabotropic Receptors in an In-Vitro Model of Parkinson’s Disease
David S. Albers, Ph.D.
Mass. General Hospital, Dept. of Brain & Cognitive Sciences

2. Analysis of Novel Gene with Highly Enriched Basal Ganglia Expression
Juan J. Canales, Ph.D.
Mass. Institute of Technology, Dept. of Brain and Cognitive Sciences

3. Genetics of MPTP-Induced Parkinsonism
Justine Cunningham, Ph.D.
St. Jude Children's Research Hospital, Dept. of Dev. Neurobiology

4. PET Imaging of Drut Naïve Hemiparkinsonian Patients with D. Agonist R-cskF2957
Joan Da Silva, Ph.D.
The Clark Institute Center of Addiction and Mental Health

5. Modeling Lewy Body Formation in Parkinson’s Disease
Matthew Ferrer, Ph.D.
Mayo Clinic

6. Parkinson’s and the Ubiquitin Pathway: Implications for Parkinson's Disease
Ashok Hedge, Ph.D.
College of Physicians & Surgeons, Center
for Neurobiology and Behavior

7. The Fruit Fly: A Model Organism to Study the Behavior and Genetics of Parkinson's
Judith Horowitz, Ph.D.
Medaille College

8. The Interaction of a-Synuclein With Vesicular Monamine Transporter in the Pathogenesis of Parkinson's Disease
Yongjian Liu, M.D.
University of California, San Francisco, Dept. of Neurology

9. The Role and Targets of Poly (ADP) Ribose Polymerase in MPTP-Induced Parkinsonism
Allen S. Mandir, M.D., Ph.D.
John's Hopkins School of Medicine, Neurology

10. Regulation of Phopholipase D: A Function for the Parkinson's Disease Gene
Andrew J. Morris, Ph.D.
SUNY-Health Sciences Center, Pharmacology

11. Clustering of the Dopamine Transporter by a-Synuclein: Implications for the Etiology of Parkinson’s Disease
Hyman B. Niznik, Ph.D.
The Clark Institute/University of Toronto

12. Manipulation of Adult Neural Stem Cells In Vivo for Treatment of Parkinson's Disease
Derek Van Der Kooy, Ph.D.
University of Biology, Dept. of Anatomy and Cell Biology

13. Utilization of Immortal Cell Lines of the Carotid Body to Treat Parkinson's Disease
Zuo-Zhong Wang, Ph.D.
University of Pittsburgh, School of Medicine Neurobiology

14. a-Synuclein-Medicated Cell Death
Benjamin Wolozin, M.D., Ph.D.
Loyola University, Stritch School of Medicine

15. A Novel Treatment of Parkinson's Disease Using the Immunomodulator AS10l
Gal Yadid, Ph.D.
Bar-Ilan University, Dept. Life Sciences

16. Delivery of L-dopa and GDNF in Animal Models of Parkinson's Disease Via Recombinant Adeo-Associated Virus Mediated Gene
Anders Bjorklund, M.D.
University of Lund, Wallenberg Neuroscience Center

17. Assessing A2a Adenosine Antagonists as a Novel Anti-parkinsonian Agent Using a A2a Receptor Knock-out Model
Jiang-Fan Chen, M.D., Ph.D.
Massachusetts General Hospital

18. Physiologic Effects of Deep Brain Stimulation in Patients with Parkinson's Disease
Robert Chen, MA, MBBChir, MSc, FRCPC
Toronto Hospital, Western Division

19. Mechanisms of MPTP-Induced DNA Damage: Studies in Genetically Engineered Mice
Marie-Francoise Chesselel, M.D., Ph.D.
UCLA School of Medicine, Dept. of Medicine

20. The Role of JNK3 Signaling Pathway in Neural Death: Practical Implication for the Study of Excitatory Phenomenon Neurodegenerative Disease with Special Reference to Parkinson’s Disease
Richard A. Flavall, Ph.D.
Yale University School of Medicine, Immunology

21. Glutamatergic Compensation After MPTP Lesioning in Mice
Michael W. Jakowec, Ph.D.
The Parkinson Institute

22. Dopamine Neural Survival in Mice Lacking Glutathione Peroxides
Un Jung Kang, M.D.
University of Chicago, Dept. of Neurology


Continue to 1998-1999 Pilot Study Grants - Grants 23-47

Return to Top

Click for a printer friendly version